Effects of glucose-lowering drugs on cardiovascular outcomes in patients with type 2 diabetes.
a Research Center for Translational Medicine , Shanghai East Hospital Affiliated to Tongji University School of Medicine , Shanghai , China.|b Department of Medicine & Therapeutics , The Chinese University of Hong Kong , Shatin , Hong Kong.
Brian
B
Tomlinson
b Department of Medicine & Therapeutics , The Chinese University of Hong Kong , Shatin , Hong Kong.
Miao
M
Hu
a Research Center for Translational Medicine , Shanghai East Hospital Affiliated to Tongji University School of Medicine , Shanghai , China.
Yuzhen
Y
Zhang
c Division of Cardiology, Department of Internal Medicine, Wan Fang Hospital , Taipei Medical University , Taipei City , Taiwan.
Paul
P
Chan
d Department of Cardiac Surgery , Shanghai East Hospital, Tongji University , Shanghai , China.
Zhong-Min
ZM
Liu
Alogliptin; dipeptidyl peptidase-4 inhibitors; empagliflozin; glucagon-like peptide-1 agonists; liraglutide; lixisenatide; saxagliptin; sitagliptin; sodium-glucose cotransporter 2 inhibitors; type 2 diabetes mellitus